ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jan 23, 2018
Bioverativ’s Takeout, Visa’s Surge, and General Electric’s Pain
From Bioverativ’s takeout to Visa’s stock price surge to General Electric’s continued pain, there’s a lot going on in the stock market. Let’s cover some ground.
Jan 23, 2018
Dropping Coverage of A Few Apparel Makers
Image Source: Kris Cardenas. Valuentum is dropping coverage of a few apparel makers to focus resources elsewhere.
Jan 23, 2018
GlaxoSmithKline: Not All Dividends Are Created Equal
Many seeking ideas to generate dividend income may be drawn to slow-growing entities with large dividend yields. However, without proper examination of the balance sheet and competitive position, an investor may enter a position banking on a steady dividend stream only to be caught by a sudden cut in the dividend. It is growing increasingly likely that GlaxoSmithKline may be ready to sacrifice the dividend on the altar in the name of additional M&A, in our view.
Jan 22, 2018
Gilead Sciences’ HCV Guidance Is the Star of the Show
Image Source: Gilead. Shares of Gilead Science have been held hostage due to the vagaries of the HCV business. The shares blasted through $100 as the initial sales ramp for its suite of HCV meds took the market by storm. The record revenues posted in 2015 proved to be unsustainable, however, as the curative nature of the treatment meaningfully decreased the eligible pool of patients much to the benefit of society. The Street subsequently punished shares of Gilead as the equity made a near roundtrip back down the high $60’s. The investment community has maintained a near-maniacal obsession with the HCV pipeline with the latest fear of a new competitor stealing share. Let's examine these key points a bit further.
Jan 21, 2018
Hanesbrands Leaps, IBM Falters and More
We were pleased to see the recent performance of Hanesbrands, and we continue to think IBM is not yet out of the woods, despite some life with respect to revenue trends. Let’s cover this and more.
Jan 19, 2018
Brewing the Next Dividend Aristocrat
Image Source: Starbucks. Most income-minded investors would love to find the next Dividend Aristocrat before it earns such a title, but many continue to focus on the stars of the past instead of working to identify up and coming dividend track records, which often carry higher dividend growth rates than the most established Dividend Aristocrats.
Jan 18, 2018
In the News: GE, O, EGO, CELG
There is a lot happening in the markets. Let’s have a look at some of the top news.
Jan 17, 2018
Dropping Coverage of the Education (For-Profit) Industry
Image Source: IowaPolitics. Valuentum is dropping coverage of the Education (For-Profit) industry to focus resources elsewhere.
Jan 14, 2018
2018 Starts Out with a Bang!
Image Shown: An ETF that measures momentum (MTUM) has done considerably better than the S&P 500 since the beginning of 2017. Among its top 5 holdings are Microsoft (MSFT), Apple (AAPL), Boeing (BA)—newsletter holdings that have had excellent value characteristics along the way. Visa (V) is also included in its top 10 holdings. Even some the most bullish and optimistic investors have been surprised by the resiliency of today’s market environment. Why does it seem appropriate to remind members that the stock market doesn’t always go straight up with almost no volatility?
Jan 12, 2018
Discount Rates, Growth Rates, and "Skin in the Game"
In episode 18 of his video series "Off the Cuff," President of Investment Research Brian Nelson talks about why it is so important for you to learn the discounted cash-flow model and how to think about discount rates and growth rates within it. He also provides a few perspectives on the concept of "skin in the game," and the areas where it might be good and the areas where it might be bad. Running time: ~12 minutes.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.